Related by context. All words. (Click for frequent words.) 67 OPAXIO 65 XYOTAX 64 picoplatin 64 Pixantrone 62 Fludara 62 pralatrexate 62 satraplatin 62 FOLOTYN 61 Zevalin 61 clofarabine 61 Clolar 61 vandetanib 61 Marqibo 61 Vectibix 60 perifosine 60 FTY# 60 Ceplene 60 T DM1 60 panitumumab 59 ZEVALIN 59 axitinib 59 Oncophage 59 TREANDA 59 Amrubicin 58 IMGN# 58 Genasense 58 Treanda 58 TRISENOX 58 EFAPROXYN 58 Taxotere ® 58 TELCYTA 58 indolent NHL 58 REVLIMID 58 L MTP PE 58 mapatumumab 58 glufosfamide 58 Actemra 58 telaprevir 57 carfilzomib 57 CoFactor 57 BAY #-# 57 Fampridine SR 57 ponatinib 57 Pixuvri 57 MyVax R 57 amrubicin 57 Velcade bortezomib 57 oral ridaforolimus 57 bendamustine 57 lupus nephritis 57 refractory Hodgkin lymphoma 57 lintuzumab 57 Jevtana 57 pertuzumab 57 tanespimycin 57 BiovaxID 57 pirfenidone 57 Revlimid 57 MOZOBIL 57 PXD# 57 aflibercept 56 Satraplatin 56 Zerenex 56 Leukine 56 ixabepilone 56 sapacitabine 56 ruxolitinib 56 VELCADE 56 romiplostim 56 Vidaza 56 maribavir 56 relapsed refractory 56 Revlimid lenalidomide 56 ADVEXIN 56 azacitidine 56 sunitinib 56 MEPACT 56 tesmilifene 56 Allovectin 7 ® 56 ofatumumab 56 TELINTRA 56 ZYBRESTAT 56 pomalidomide 56 sorafenib 56 MyVax 56 FavId 56 IL# PE#QQR 56 elotuzumab 56 Junovan 56 metastatic renal cell carcinoma 56 EOquin TM 56 Ceflatonin 56 ASA# 56 refractory PTCL 56 SinuNase 56 relapsed refractory multiple myeloma 55 ipilimumab 55 teriflunomide 55 TEMODAL 55 cutaneous T cell 55 blinatumomab 55 Avastin bevacizumab 55 lymphoma CTCL 55 REOLYSIN ® 55 metastatic colorectal cancer 55 PEG PAL 55 alvimopan 55 cetuximab 55 bafetinib 55 Targretin 55 ambrisentan 55 AP# [003] 55 dirucotide 55 Rituxan 55 refractory systemic ALCL 55 mRCC 55 Herceptin trastuzumab 55 Tavocept 55 valopicitabine 55 vinorelbine 55 ridaforolimus 55 TYSABRI 55 Rituxan rituximab 55 myelofibrosis 55 talactoferrin 55 StaphVAX 55 TORISEL 55 celgosivir 55 Xcytrin 55 systemic ALCL 55 YERVOY 55 nilotinib 55 Taxotere R 55 velaglucerase alfa 55 Evoltra TM 55 RSR# 55 belinostat 55 dasatinib 55 lumiliximab 55 Campath 55 Hycamtin 55 OMAPRO 55 Avastin 55 Telavancin 55 Torisel 55 Folotyn 55 T Pred 55 pegloticase 55 Acetavance 55 voreloxin 55 platinum refractory 55 obatoclax 55 registrational trial 55 denosumab 54 HER2 positive metastatic breast 54 Nexavar 54 Onrigin 54 B CLL 54 telbivudine 54 TRISENOX ® 54 phase IIb clinical 54 sorafenib Nexavar 54 PIX# trial 54 RG# [001] 54 plus gemcitabine 54 VIDAZA 54 Dacogen injection 54 nimotuzumab 54 Krystexxa 54 VEGF Trap 54 Cloretazine R VNP#M 54 ERBITUX 54 Amigal 54 TOCOSOL Paclitaxel 54 INCB# [002] 54 TTF Therapy 54 surrogate endpoint 54 ganetespib 54 relapsing remitting multiple sclerosis 54 iniparib 54 Zenvia 54 enzastaurin 54 Afinitor 54 docetaxel 54 Nexavar sorafenib 54 cabazitaxel 54 Taxotere chemotherapy 54 Vandetanib 54 brentuximab vedotin 54 relapsed ovarian cancer 54 temsirolimus 54 ATryn R 54 HuMax CD4 54 Riquent 54 anidulafungin 54 Phenoptin 54 bone metastases 54 KRN# 54 Combidex 54 PIX# [002] 54 PROVENGE 54 MabThera Rituxan 54 forodesine 54 orBec R 54 refractory multiple myeloma 54 alvespimycin 54 BENLYSTA 54 zoledronic acid 54 neratinib 54 oritavancin 54 Soliris TM eculizumab 54 SILENOR TM 54 Rituximab 54 PROSTVAC ® 53 otelixizumab 53 dacetuzumab 53 palifosfamide 53 bevacizumab 53 leukemia CLL 53 biologic therapy 53 relapsed refractory aggressive 53 mCRC patients 53 sunitinib malate 53 registrational 53 Azixa 53 plus dexamethasone 53 tocilizumab 53 EGFR expressing mCRC 53 Bortezomib 53 posaconazole 53 REVLIMID lenalidomide 53 temozolomide 53 metastatic melanoma 53 MAA submission 53 Nplate 53 Bronchitol 53 Arzerra 53 omacetaxine 53 FOLFOX 53 advanced NSCLC 53 romidepsin 53 Perifosine 53 MabCampath 53 Dacogen 53 Advexin 53 ELACYT 53 figitumumab 53 Xyotax 53 relapsed SCLC 53 Insegia 53 previously untreated follicular 53 TNFerade 53 INC# 53 Cloretazine 53 oxymorphone ER 53 ACTEMRA 53 rituximab 53 Pirfenidone 53 gemcitabine 53 eniluracil 53 decitabine 53 cytotoxic chemotherapy 53 Promacta 53 elesclomol 53 lenalidomide 53 cintredekin besudotox 53 prGCD 53 topotecan 53 5-FU/LV 53 NOXAFIL 53 SUTENT 53 Neurodex 53 Proxinium TM 53 Viramidine 53 MabThera 53 pazopanib 53 ferumoxytol 53 dacarbazine 53 Tarceva erlotinib 53 INCB# [001] 53 Fusilev 52 refractory chronic lymphocytic 52 Celgene Revlimid 52 tivozanib 52 recurrent GBM 52 pivotal Phase 52 XL# [003] 52 brain metastases 52 Tarceva TM 52 telavancin 52 Abraxane 52 mitoxantrone 52 nab paclitaxel 52 Glivec 52 ocrelizumab 52 abatacept 52 YONDELIS 52 tafamidis 52 locoregional 52 bevacizumab Avastin 52 chemotherapy regimens 52 Icatibant 52 fluoropyrimidine 52 zalutumumab 52 confirmatory Phase III 52 OvaRex ® MAb 52 FOLFIRI 52 Tasigna nilotinib 52 Virulizin R 52 REVLIMID R 52 PREZISTA r 52 Zelrix 52 docetaxel chemotherapy 52 Rasilez Tekturna 52 Mylotarg 52 TYKERB 52 rNAPc2 52 abiraterone 52 CINTREDEKIN BESUDOTOX 52 MoxDuo IR 52 TRIOLEX 52 Clofarabine 52 monotherapy 52 anti TNF 52 myelodysplastic syndromes 52 fingolimod 52 Nexavar ® 52 Cloretazine ® 52 ISENTRESS 52 Phase Ib 52 PhosLo 52 capecitabine 52 metastatic HRPC 52 ZOLINZA 52 Canvaxin 52 PROMACTA 52 APF# 52 infusional 5-FU/LV 52 leucovorin 52 Tasigna 52 IMiDs 52 lapatinib 52 octreotide 52 dimebon 52 Provenge 52 ABRAXANE 52 BEXXAR 52 oral anticoagulant 52 Phase 2b trial 52 Ilaris 52 irinotecan 52 Xgeva 52 Telcyta 52 mycophenolate mofetil 52 refractory AML 52 vemurafenib 52 Prochymal 52 HoFH 52 hepatocellular carcinoma 52 cytarabine 52 febrile neutropenia 52 Stimuvax 52 myelodysplastic syndromes MDS 52 platelet inhibitor 52 #D#C# 52 Phase 2b clinical 52 anti leukemic 52 Alzhemed TM 52 carboplatin paclitaxel 52 bazedoxifene 52 Telaprevir 52 PREOS 52 Alemtuzumab 52 APPRAISE 52 trabectedin 52 subcutaneous formulation 52 Omigard 52 RITUXAN 52 Allovectin 7 R 52 Neulasta ® 52 Arixtra 52 Galvus 52 NPSP# 52 Gliadel Wafer 52 Sandostatin LAR 52 oral mucositis 52 recurrent glioblastoma multiforme 52 vosaroxin 52 XGEVA 52 pemetrexed 51 everolimus 51 Xanafide 51 cell chronic lymphocytic 51 NSCLC 51 Pemetrexed 51 imatinib 51 docetaxel Taxotere R 51 chronic myeloid leukemia CML 51 PrevOnco 51 rhThrombin 51 panitumumab Vectibix 51 recurrent NSCLC 51 paliperidone ER 51 daclizumab 51 Genz # 51 MBP# [001] 51 cilengitide 51 ADVENTRX 51 MyVax personalized immunotherapy 51 chlorambucil 51 Hematide 51 Ambrisentan 51 galiximab 51 CHOP chemotherapy 51 HGS ETR1 51 eltrombopag 51 Ocrelizumab 51 fludarabine 51 Cimzia 51 alogliptin 51 viral kinetic 51 Tarceva 51 heavily pretreated 51 sorafenib Nexavar ® 51 sorafenib tablets 51 mifamurtide 51 TYZEKA 51 Panitumumab 51 baminercept 51 Fibrillex TM 51 EOquin 51 chemotherapeutic regimen 51 neoadjuvant therapy 51 BRAF inhibitor 51 standard chemotherapy regimen 51 bevacizumab Avastin ® 51 iclaprim 51 Marketing Authorization Application 51 MAGE A3 ASCI 51 MYDICAR ® 51 comparator arm 51 cetuximab Erbitux R 51 rivaroxaban 51 ACZ# 51 alemtuzumab 51 hepatocellular carcinoma HCC 51 low dose cytarabine 51 refractory acute myeloid 51 allogeneic stem cell 51 OncoVEX 51 follicular lymphoma 51 Hycamtin ® 51 capecitabine Xeloda R 51 Xinlay 51 Dasatinib 51 REVLIMID ® 51 Eloxatin 51 chronic lymphocytic leukemia CLL 51 CA4P 51 Vectibix panitumumab 51 Increlex ® 51 chronic gout 51 Entereg 51 bortezomib 51 Cytoxan 51 metastatic GIST 51 regorafenib 51 iloperidone 51 Sprycel 51 Onco TCS 51 gefitinib 51 anticancer therapy 51 thymalfasin 51 Genasense ® 51 Mozobil 51 HRPC 51 follicular NHL 51 Orathecin 51 MYLOTARG 51 Clolar ® 51 cancer mCRC 51 CPOP R 51 liver metastases 51 UPLYSO 51 Civacir 51 trastuzumab DM1 51 phase Ib 51 Carfilzomib 51 Multaq R 51 Hodgkin lymphoma NHL 51 Medicinal Products EMEA 51 Phase III clinical 51 relapsed multiple myeloma 51 chronic myeloid leukemia 51 panobinostat 51 MGCD# [002] 51 Mepact 51 Doxil 51 bosentan 51 AEG# 51 afatinib 51 Onbrez Breezhaler 51 Doxil ® 51 Synvisc One 51 FOLOTYN ® 51 palifermin 51 TMC# [001] 51 Horizant 51 Mitoxantrone 51 Corlux 51 patients evaluable 51 omacetaxine mepesuccinate 51 Cinryze 51 NDA submission 51 mCRC 51 ANA# 51 Asentar 51 Zytiga 51 depsipeptide 51 GVAX 51 carboplatin 51 MyVax ® 51 Ranexa 51 Taxotere 50 riociguat 50 OncoVEX GM CSF 50 efficacy endpoints 50 Hedgehog Pathway Inhibitor 50 pivotal Phase III 50 Phase IIIb clinical 50 MGd 50 Gilenia 50 Urocidin 50 refractory CLL 50 relapsed myeloma 50 LymphoStat B 50 lapatinib Tykerb 50 MGCD# [001] 50 Zalbin 50 orBec ® 50 vilazodone 50 Panzem R NCD 50 Bezielle 50 TNF alpha inhibitor 50 refractory APL 50 methylnaltrexone 50 NEBIDO 50 Pazopanib 50 Telintra 50 HGS# 50 metastatic kidney 50 velafermin 50 refractory peripheral T 50 eribulin 50 fidaxomicin 50 cinacalcet HCl 50 ALIMTA 50 CR# vcMMAE 50 pegfilgrastim 50 C1 INH 50 Allovectin 7 50 free survival PFS 50 NUVIGIL 50 AFREZZA 50 oxaliplatin 50 disease modifying 50 Actemra tocilizumab 50 PREZISTA rtv 50 Stedivaze 50 oblimersen 50 Navelbine ® 50 ularitide 50 Increlex R 50 non metastatic osteosarcoma 50 brivaracetam 50 veltuzumab 50 randomized Phase 50 tamibarotene 50 relapsed CLL 50 VPRIV 50 Romidepsin 50 Menerba 50 Troxatyl 50 tolevamer 50 DCVax R Brain 50 Adalimumab 50 IV metastatic melanoma 50 Gemzar ® 50 Bevacizumab 50 Ventavis 50 PRTX 50 IRESSA 50 Fludara ® 50 ORENCIA R 50 refractory NSCLC 50 mipomersen 50 IRX 2 50 Azedra 50 randomized multicenter Phase III 50 HspE7 50 eculizumab 50 heavily pretreated patients 50 Erbitux 50 unique alkylating agent 50 asenapine 50 RDEA# 50 cediranib 50 dose escalation Phase 50 Alocrest 50 LEP ETU 50 elagolix 50 Prestara 50 Arzerra ofatumumab 50 Firazyr 50 CMV disease 50 Docetaxel 50 evaluable patients 50 FASLODEX 50 Eribulin 50 cladribine 50 REOLYSIN R 50 Halaven 50 Phase IIb trial 50 pegylated interferon alfa 2b 50 Dendreon Provenge 50 Noxafil 50 Virulizin ® 50 tecarfarin 50 HuLuc# 50 TAXOTERE R 50 CellCept 50 hormone refractory prostate cancer 50 Iressa 50 Renvela 50 BLA submission 50 PEG SN# 50 rindopepimut 50 cangrelor 50 CLL 50 Nuvion 50 AVONEX 50 vismodegib 50 torezolid phosphate 50 relapsed 50 MERLIN TIMI 50 calcineurin inhibitors 50 Kuvan 50 docetaxel Taxotere 50 PROSTVAC TM 50 dexanabinol 50 durable remissions 50 Tykerb 50 Gleevec imatinib 50 adecatumumab 50 Velcade 50 Biologics License Application BLA 50 Cimzia ® 50 Targretin capsules 50 Novartis Zometa 50 NB S# 50 Abiraterone acetate 50 randomized Phase 2b 50 HGS ETR2 50 darapladib 50 Epoetin alfa 50 G CSF 50 hypomethylating agents 50 trastuzumab Herceptin R 50 saxagliptin 50 QAB# 50 follicular non 50 recurrent ovarian cancer 50 PROVENGE ® 50 Sebivo 50 Navelbine 50 abiraterone acetate 50 oral FTY# 50 relapsing MS 50 ezogabine 50 teduglutide 50 PNH patients 50 LibiGel ® 50 PRT# 50 secondary efficacy endpoints 50 phase IIb trial 50 Raptiva ® 50 dose escalation clinical 50 lorcaserin 50 Certican 50 oral cladribine 50 Campath ® 50 Omnitarg 50 ANTEGREN 50 standard chemotherapy regimens 50 IMA# 50 pegylated interferon 50 vorinostat 50 voclosporin 50 Study GL# 50 FOLFOX4 50 regadenoson 50 BLP# Liposome Vaccine 50 rituximab Rituxan 50 lorcaserin NDA 50 vernakalant 50 peginesatide 50 R sorafenib tablets 50 Hepsera 50 RE SURGE 50 Northera 50 PegIntron 50 Exjade 50 Gleevec imatinib mesylate 50 Cladribine Tablets 50 severe hypercholesterolemia 49 humanized anti 49 chemoradiation 49 plus prednisone 49 hA# 49 Biologics License Application 49 REOLYSIN 49 Sutent 49 soft tissue sarcomas 49 Vasovist 49 refractory indolent non 49 BLA filing 49 multiple myeloma 49 Vilazodone 49 dasatinib Sprycel ® 49 L BLP# 49 pegylated interferon alpha 49 dabigatran etexilate 49 Fodosine 49 Anturol 49 sipuleucel T 49 bosutinib 49 acute myelogenous leukemia AML 49 EndoTAG TM -1 49 Cethrin 49 refractory CTCL 49 prasugrel 49 BYDUREON 49 DOXIL 49 AZILECT R 49 PEG INTRON 49 ACTEMRA TM 49 SEBIVO 49 Personalized Immunotherapy 49 personalized immunotherapy 49 BrachySil 49 Rituxan MabThera 49 Plicera 49 brentuximab vedotin SGN 49 alfa 2a 49 Ceflatonin ® 49 invasive candidiasis 49 IMC A# 49 Irinotecan 49 Panzem 49 Locteron 49 CAELYX 49 Tracleer 49 gadobutrol 49 ZEVALIN ® 49 Phase Ib clinical 49 Dyloject 49 neuroendocrine tumors 49 Zolinza 49 L DOS# 49 REMICADE ® 49 placebo controlled Phase III 49 Cotara 49 milatuzumab 49 MKC# PP 49 peg interferon 49 adalimumab 49 ranolazine 49 Imagify 49 Tamibarotene 49 Carboplatin 49 Increlex 49 ITAX 49 xanthine oxidase inhibitor 49 apaziquone 49 RAD# [003] 49 investigational compound 49 Itopride 49 mertansine 49 Bydureon 49 Chemophase 49 Cloretazine R 49 ustekinumab 49 almorexant 49 Ixempra 49 European Medicines Evaluation 49 INTELENCE 49 MYDICAR 49 DLBCL 49 clinical trial 49 sorafenib Nexavar R 49 refractory 49 NEUPOGEN 49 metastatic hormone refractory 49 Everolimus 49 Voraxaze ™ 49 FluCAM 49 invasive fungal infections 49 darusentan 49 Rasilez 49 AQ4N 49 Aflibercept 49 HER2 positive breast cancer 49 renal cell carcinoma 49 hoFH 49 Follicular Lymphoma 49 taxane 49 relapsed refractory ALL 49 ILLUMINATE 49 AGGRASTAT ® 49 lorvotuzumab mertansine 49 trastuzumab DM1 T DM1 49 Phase Ib study 49 Topical Interferon Alpha 2b 49 ELOXATIN 49 Evoltra 49 DASISION 49 Taxotere docetaxel 49 clinical trials 49 Reolysin 49 Cladribine 49 lubiprostone 49 Golimumab 49 Albuferon 49 dose dexamethasone 49 HCV SPRINT 49 gastrointestinal stromal tumors 49 PDX pralatrexate 49 Platinol 49 tezampanel 49 nitazoxanide 49 gemcitabine chemotherapy 49 bortezomib Velcade R 49 DU #b 49 treatment regimens 49 ARIXTRA 49 CTCL 49 erlotinib Tarceva ® 49 renal toxicity 49 rosuvastatin 49 aHUS 49 Dyloject TM 49 Alpharadin 49 MAXY G# 49 ISTODAX 49 KRAS mutant tumors 49 Pfizer Sutent 49 imetelstat 49 chronic angina 49 goserelin 49 AzaSite Plus 49 olmesartan 49 heterozygous FH 49 trastuzumab 49 metastatic RCC 49 Advagraf 49 Esbriet 49 crizotinib PF # 49 BCIRG 49 Omapro 49 CLL8 49 Santhera 49 docetaxel Taxotere ® 49 Nebido 49 orBec 49 dalbavancin 49 remission induction 49 Phase 2a trial 49 Fablyn 49 ONTAK 49 Yervoy 49 Cetrorelix 49 Sutent sunitinib 49 GRNVAC1 49 ATryn ® 49 Restanza 49 radiation sensitizer 49 oncology indications 49 Atiprimod 49 Romiplostim 49 relapsing multiple sclerosis 49 tipifarnib 49 Removab 49 elacytarabine 49 Benlysta belimumab 49 gastrointestinal stromal tumor GIST 49 Annamycin 49 Degarelix 49 Phase 2b study 49 Rhucin 49 Traficet EN 49 Antegren 49 Octreolin 49 pegylated interferons 49 SPRYCEL 49 Exforge 49 sBLA 49 CD# antibody [001] 49 ZACTIMA 49 KRAS status 49 talabostat 49 Amgen Vectibix 49 Camptosar ® 49 metastatic renal cell 49 dose escalation 49 indacaterol 49 placebo controlled Phase 49 exenatide 49 hematologic toxicity 49 custirsen 49 rFVIIa 49 APTIVUS R 49 Gemzar 49 Replagal 49 interferon therapy 49 hormone refractory metastatic prostate 49 boceprevir 49 Dabigatran etexilate 49 NYHA Class II 49 dirucotide MBP# 49 complete remissions 49 DR Cysteamine 49 imatinib mesylate 49 myelofibrosis MF 49 dose cohorts 49 BENLYSTA ® 49 refractory angina 49 cancer immunotherapies 49 Imprime PGG 49 PEG interferon 49 oral methylnaltrexone 49 NEUMUNE 49 Tesetaxel 49 Novartis Gleevec 49 Lialda 49 Laquinimod 49 Daclizumab 49 Phase #b/#a clinical 49 entecavir 49 HCV RESPOND 2 49 PEGylated interferon beta 1a 49 PEG Interferon lambda 49 albinterferon alfa 2b 49 seliciclib 49 relapsed follicular 49 Xeloda ® 49 Cimzia ® certolizumab pegol 49 atacicept 49 THALOMID 48 Adentri 48 Tekturna HCT 48 Alfimeprase 48 Muraglitazar 48 Rezular 48 SCCHN 48 fenofibrate 48 Egrifta 48 ThermoDox ® 48 Pegintron 48 Stimuvax R 48 belatacept 48 Phase III pivotal 48 phase IIb 48 letrozole 48 Bayer Nexavar 48 Hepatocellular Carcinoma HCC 48 aflibercept VEGF Trap 48 HuMax EGFr 48 dasatinib Sprycel 48 FOLFIRI alone 48 Feraheme 48 HCV infection 48 prostate cancer CRPC 48 peg IFN 48 ZADAXIN 48 superficial bladder cancer 48 SANVAR 48 micafungin 48 ATACAND 48 Phase III clinical trials 48 Board DSMB 48 MEND CABG II 48 BiovaxID TM 48 diabetic neuropathic pain 48 canakinumab 48 Phase Ib II 48 XELOX 48 CIMZIA TM 48 ACAPODENE TM 48 Voraxaze